• Vectorious Medical Technologies

  Participated · Equity · Feb 2015

  Vectorious has developed a miniature wireless sensory implant and an external home unit that provide daily, ‘push-button’ left atrial pressure readings to give early physiological indication of cardiac decompensation. The system is designed for minimally invasive delivery and aims to improve CHF patient quality of life and reduce hospital readmissions by enabling optimized, physician-managed closed-loop therapy. The device measures left atrial pressure directly and transmits easy-to-access data for outpatient monitoring. According to the company the implant is safe and intended for low‑risk delivery with reduced long‑term complications. Commercial availability is currently limited—the device is not available for sale in the United States or internationally. Financially, Vectorious has secured venture and grant funding including a $9.5M Series B and earlier grants from the Israel Innovation Authority and a $2.2M Horizon 2020 award. Vectorious Medical Technologies is a Tel Aviv, Israel-based medical device company developing an implantable cardiac monitoring system for patients with congestive heart failure. The system leverages miniature sensing and wireless communications to enable daily readings of left atrial pressure. Led by founder and CEO Oren Goldstein, the company aims to advance continuous hemodynamic monitoring for CHF management. Vectorious closed a $5M financing to fund further development and clinical initiation. The company plans to use the proceeds to initiate first-in-human trials in collaboration with senior cardiologists from the U.S. and Israel.

• Juventas Therapeutics

  Participated · Series B · Jul 2012

  Juventas Therapeutics is focused on developing non-viral gene therapies for advanced cardiovascular diseases, with its lead candidate JVS-100 undergoing evaluation in clinical studies. JVS-100 is being developed under an exclusive license from the Cleveland Clinic. The company was founded in 2007 and is based in Cleveland, Ohio, and is led by president and CEO Rahul Aras, Ph.D. Juventas recently expanded its Board of Directors with the addition of James Boland. Financially, the company secured a financing package comprising equity and debt to support its clinical-stage programs. The financing details indicate a mix of Series B-2 equity and debt with milestone-linked additional capital available. Juventas Therapeutics, founded in 2007 and led by President & CEO Rahul Aras, Ph.D., is a Cleveland, OH-based clinical-stage regenerative medicine company advancing JVS-100, its lead product encoding Stromal cell‑Derived Factor 1 (SDF‑1). JVS-100 has been shown to repair damaged tissue by recruiting circulating stem cells to sites of injury, preventing ongoing cell death, and restoring blood flow. The company closed a $22.2M Series B financing and intends to use the funds to complete ongoing Phase II clinical trials. The Phase II trials are investigating JVS-100 in patients with chronic heart failure and critical limb ischemia, and both trials are actively enrolling. The financing supports continued clinical development of the therapy and associated programs.

No current team members are available.